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Background. The aim of the study was to evaluate the added value of the apparent diffusion coefficient (ADC) of 
diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with rectal cancer who received neoadjuvant 
chemoradiotherapy (CRT). The use of DW-MRI for response evaluation in rectal cancer still remains a widely investigat-
ed issue, as the accurate detection of pathologic complete response (pCR) is critical in making therapeutic decisions.
Patients and methods. Thirty-three patients with locally advanced rectal cancer were evaluated retrospectively 
by MRI in addition to diffusion-weighted images (DWI) and its ADC pre- and post- neoadjuvant CRT. These patients 
subsequently underwent curative-intent surgery. Tumor staging by MRI and ADC value were compared with histo-
pathological findings of the surgical specimen. 
Results. MRI in addition to DWI had a sensitivity of 96.1%, specificity of 71.4%, positive predictive value of 92.5%, and 
negative predictive value of 83.3% in the detection of pCR. The pre-CRT ADC alone could not reliably predict the 
pCR group. Post-CRT ADC cutoff value of 1.49 x 10-3 mm2/s had the highest accuracy and allowed a 16.7% increase in 
negative predictive value and 3.9% increase in sensitivity. Patients with pCR to neoadjuvant treatment differed from 
the other groups in their absolute values of post-CRT ADC (p < 0.01). 
Conclusions. The use of post-CRT ADC increased the diagnostic performance of MRI in addition to DWI in predicting 
the final pathologic staging of rectal carcinoma. 
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Introduction
Restaging locally advanced rectal cancer after neo-
adjuvant chemoradiotherapy (CRT) is critical in 
making therapeutic decisions based on magnetic 
resonance imaging (MRI). The diagnostic perfor-
mance of this radiological method is reduced in 
the restaging of patients undergoing neadjuvant 
therapy, because of the difficulty in differentiat-
ing residual tumour within radiotherapy induced 
fibrosis.1-3
Several publications of the last decade reported 
the potential use of diffusion-weighted magnetic 
resonance imaging (DW-MRI) through its apparent 
diffusion coefficient (ADC) as an additional way to 
clarify the radiological and biological behavior of 
these tumors.4 This technique measures the char-
acteristics of water diffusion in a tissue, which de-
pends on the cell density, vascularization, extracel-
lular viscosity, and integrity of the cell membrane. 
Any change in tissue components, including the 
ratio of protons of water molecules between the 
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extracellular and intracellular environment, may 
modify the diffusion coefficient of water.5-7
Previous studies of different tumor types have 
suggested that this quantitative interpretation of 
the ADC could be used as a reliable biomarker of 
response to neoadjuvant treatment.5,7-9 
However, there is no consensus regarding the 
use of different ADC cutoff values or their even-
tual clinical use in daily practice in the evaluation 
of response to CRT in rectal cancer. Small-scale 
studies with varying methodologies and conflict-
ing conclusions have contributed to the wide range 
of results.1-10
Given this knowledge gap, the objective of this 
study was to evaluate the diagnostic performance 
of MRI in addition to diffusion-weighted images 
(DWI) and measure the tumor’s ADC, before and 




Forty-four patients were diagnosed and treated for 
rectal cancer in the State Public Servant Hospital of 
São Paulo (Brazil), from February 2010 to May 2014. 
This study was performed in accordance with the 
guidelines of the Helsinki Declaration, fulfilling all 
requirements for retrospective studies in humans. 
All the images were accessed in the hospital data-
base, with the approval of the Ethics Committee 
of our institution (number 04989912.8.0000.5463). 
Informed consent was not obtained as patient re-
cords and information was anonymized and de-
identified prior to all the analysis of this pure ret-
rospective study.
The inclusion criteria were the following: pa-
tient with histological biopsy of rectal adenocarci-
noma, completion of a full course of neoadjuvant 
CRT, and having undergone MRI and DW-MRI 
pre- and post-CRT. Thirty-eight patients met the 
above criteria. The exclusion criteria were the fol-
lowing: failure to obtain a specimen for pathologi-
cal examination when the surgery was contrain-
dicated during treatment, a history of previous 
pelvic irradiation, and subjects with missing data. 
Among 38 patients, 5 patients were excluded due 
to disease progression (n = 1), missing data (n = 1) 
and previous pelvic irradiation (n = 3). Thirty-three 
patients remained in the final study population, 18 
males and 15 females. The median age was 59 (± 
11.53) years with a range of 36–80 years. Surgery 
performed included low anterior resection (n = 15), 
abdominoperineal resection (n = 15), and pelvic 
exenteration (n = 3). The clinical characteristics are 
summarized in Table 1. 
Neoadjuvant chemoradiation therapy
The neoadjuvant CRT regime used in all patients 
consisted of radiation to a total dose of 4500 cGy, 
divided into 5 days per week, a 28-day treatment 
period, and one boost of 540 cGy. This regimen was 
associated with the use of 5-fluorouracil at a dose 
of 350 mg/m2/day and folinic acid at a dose of 20 
mg/m2/day, in bolus for 5 days in the first and fifth 
weeks of radiation therapy. 
Histopathological examination of the 
surgical specimens
The histopathological analyzes were performed 
by expert colorectal pathologists subspecialized 
in gastro-intestinal pathology, who had no ra-
diographic information. Hematoxylin and eosin 
(H&E)-stained slides were used for microscopic 
analysis in all 33 subjects. The standard of reference 
was based on pathological staging (TNM staging 
system).11 The histopathological parameters used 
TABLE 1. The patients’ clinical characteristics and patohystologic characteristics of 
the tumor
 All pCR non-pCR
Average age, years 59.6 ±11.5 58.5 ±11.2 59.9 ±11.8
Gender*
 Male 18 5 13
 Female 15 2 13
Clinical T stage pre-CRT 
(MRI classification)*
 T2 3 1 2
 T3 23 5 18
 T4 7 1 6
Average tumor distance 
to the anus (cm)* 5.1 (± 2.2) 6.1 (± 1.3) 4.8 (± 2.3)
Type of resection*
 Low anterior resection 15 3 12
  Abdominoperineal resection 15 4 11
 Pelvic exenteration 3 0 3
Histologic grade (biopsy)*
 Well differentiated 6 2 4
 Moderately differentiated 23 4 19
 Poorly differentiated 4 1 3
* = number of individuals; CRT = chemoradiotherapy; pCR = pathologic complete response
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in this study were the maximum degree of tumor 
penetration in the rectal wall, the circumferential 
and longitudinal resection margin, and the pres-
ence or absence of intramural mucin. A pathologic 
complete response (pCR) was defined as no viable 
cells present on pathological examination of the 
surgical specimens.11
Imaging technique
The mean interval between pre-CRT MRI and the 
start of the neoadjuvant treatment was 20 ± 3 days. 
The mean interval between the completion of CRT 
and post-CRT MRI for response evaluation was 58 
± 8.8 days.
The MRI equipment used in the study was a 
1.5 Tesla whole-body system (Achieva®/Philips 
Medical Systems, Best, Netherlands), with a 
16-channel phased-array coil. The sequences used 
and their specifications were sagittal T2-weighted 
(T2W) MRI fast spin echo (repetition time/echo 
time [TR/TE]: 5030/100 ms; field of view [FOV]: 20 
cm; gap: 0.5 mm; section thickness: 3 mm; matrix 
size: 268 x 210; axial T2W MRI fast spin echo; TR/
TE: 4681/90 ms; FOV: 20 cm; gap: 0.3 mm; section 
thickness: 3 mm; and matrix size: 212 x 168). Axial 
DW-MRI were obtained using the single-shot echo 
planar imaging technique with the following pa-
rameters: TR/TE: 2800/70 ms; gap: 1 mm; slice 
thickness: 3 mm; matrix size: 104 x 100; and field of 
view: 20 cm. The axial sequences were obtained in 
the perpendicular plane to the longitudinal axis of 
rectal cancer. All sequences (including DW-MRI) 
were used for conventional MRI reading. In all 
MRIs the standard of reference was based on previ-
ous radiologic staging protocols and T2W images 
were used to help correctly identify the tumor, if 
that was the case.10,21
The diffusion-weighted images were acquired 
using four different b-values (b = 0, 50, 500 and 
1000 s/mm2). Patients did not receive antispasmod-
ic medication or bowel preparation before MRI 
examinations. Two experienced researchers in pel-
vic MRI and DW-MRI (JFF and TB), in consensus, 
blinded to patients’ data and surgical or pathologi-
cal results, reviewed the anonymized DICOM files, 
using computer software (iQ-View, version 2.7, 
IMAGE Information Systems, London, UK).
Image analysis
The diffusion-restricted area was characterized on 
one single slice, as the region with the most promi-
nent restrictive diffusion (hyperintense signal) on 
DW-MRI (b = 1000 s/mm2). This same region of 
interest (ROI) was identified and superimposed 
on the ADC map as a low signal area, which was 
reconstructed automatically by the computer soft-
ware on a pixel-by-pixel basis, avoiding T2 shine-
through effect. The tumors’ ADC value was ob-
tained through the calculation of the ROI, manu-
ally designed, in which the whole tumor area was 
depicted and delineated, excluding visible necrotic 
or cystic portions and distortion artifacts. For crite-
ria of magnetic resonance complete response, the 
residual tumor was absent in all sequences, and the 
ROI included the areas of fibrosis, which was char-
acterized by the hypointense area on T2W and no 
residual hyperintense signal on high b-value DW-
MRI (Figure 1).
Statistical analysis
The statistical analysis investigated the following 
aspects: calculation of diagnostic performance of 
conventional MRI and combined set of conven-
tional MRI in addition to DWI (sensitivity, speci-
ficity, positive predictive value and negative pre-
dictive value); Hypothesis test - two-way ANOVA 
(Analysis of Variance) using two factors: staging 
(ranging from ypT0 to ypT4) and treatment sta-
tus (pre- or post-CRT) with Bonferroni test post-
FIGURE 1. Sample of a T2-weighted MRI, DW-MRI (b-value 1000 s/mm2), and ADC 
map from a locally advanced rectal tumor. The red arrows point to different 
aspects of the left lateral pre-CRT tumor area. The yellow arrows point to the cancer 
shrinkage in the post-CRT. Pre- and post-CRT ADC values were 0.92 x 10-3 mm2/s and 
1.50 x 10-3 mm2/s, with pCR in the surgical specimen.
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hoc; Student t-test for comparison after normality 
test; Correlation between post-CRT ADC values 
and final T staging with Spearman correlation; 
Gaussianity tests and the estimation of a Gaussian 
distribution of post-CRT ADC. 
Statistical analyzes were performed using the t 
and ANOVA tests, conducted with Epi Info soft-
ware (version 3.3.2, Control Diseases Center, 
Atlanta, GA, USA). The receiver operating char-
acteristics (ROC) curves were used to analyze the 
different cutoff values, aiming at the point of high-
est sensitivity and specificity to the differentiation 
between pCR and non-pCR. The analyzes of ROC 
curves and the gaussianity tests were performed 
using SPSS for Windows (version 10, IBM SPSS, 
Chicago, IL, USA). Estimates of power analysis 
were calculated for each sample using Stata soft-
ware version 8.2 (Stata, College Station, TX, USA). 
The study had a 95% confidence level (α = 0.05), 
and the value of p ≤ 0.05 determined the signifi-
cance in all tests.
Results
Treatment characteristics
All patients were operated on with the total meso-
rectal excision technique.12 The mean interval be-
tween the end of neoadjuvant CRT and surgery 
was 77 ± 9.1 days. The longitudinal and circumfer-
ential resection margins of the specimen were free 
of cancer in all 33 patients. pCR occurred in 21.2% 
(7/33); ypT1 in 3.0% (1/33), ypT2 in 30.3% (10/33), 
ypT3 in 27.3% (9/33) and ypT4 in 18.2% (6/33) 
patients. Small amount of intramural mucin oc-
curred in 8 (24.2%) patients, and half of these had 
pCR. Mesorectal fascia involvement occurred in 8 
(24.2%) cases. The mean time interval between the 
restaging MRI and surgery was 21 ± 13.7 days.
Diagnostic performance of conventional 
MRI and combined set of conventional 
MRI in addition to DWI 
For detecting the pCR group, conventional post-
CRT T2W MRI had a sensitivity of 86.9% (20/23; 
95% CI: 0.65 to 0.96), specificity of 50% (5/10; 95% 
CI: 0.20 to 0.79), positive predictive value of 80% 
(20/25; 95% CI: 0.58 to 0.92), and negative predictive 
value of 62.5% (5/8; 95% CI: 0.25 to 0.89). Post-CRT 
MRI in addition to DWI had a sensitivity of 96.1% 
(25/26; 95% CI: 0.78 to 0.99), specificity of 71.4% 
(5/7; 95% CI: 0.30 to 0.94), positive predictive value 
of 92.6% (25/27; 95% CI: 0.74 to 0.98), and negative 
predictive value of 83.3% (5/6; 95% CI: 0.36 to 0.99). 
MRI in addition to DWI also increased the overall 
accuracy of conventional MRI from 75.7% to 81.8%. 
These aspects are summarized in Table 2.
Pre-CRT ADC value
The average pre-CRT ADC value was 1.01 ± 
0.05x10-3 mm2/s and did not vary as a function of 
tumor staging found in the surgical specimen (p > 
0.05).
Post-CRT ADC value
Post-CRT ADC values differed in each T stage 
group (p < 0.01). Due to the small sample of ypT1, 
this comparison was impaired, and there was no 
statistical difference (p > 0.05). 
Analyzing the distribution of the post-CRT ADC 
values and its correlation with the result of the 
pathological examination, we found a significant 
statistical correlation between them ( Spearman’s 
Rho = -0.54 which indicate a moderate negative 
correlation; 95% confidence interval -0.75 to -0.24). 
The pCR ADC-median value (1.53 x 10-3 mm2/s) 
is far away from the lower (1.04 x 10-3 mm2/s) and 
upper (1.31 x 10-3 mm2/s) quartiles - 25th and 75th 
percentiles, respectively - of the non-pCR box (un-
paired t test, p < 0.01). 
These quantitative aspects of the ADC and the 
rectal cancer pathological findings are shown in 
Figure 2 A, B, C. 
Using the post-CRT ADC values, the ROC curve 
was constructed. The cutoff value of 1.32 x 10-3 
mm2/s obtained a specificity of 100.0% (95% CI: 
0.56 to 1.00) and sensitivity of 80.8% (95% CI: 0.60 
to 0.92), with 84.8% accuracy. All patients who had 
pCR were allocated above this value. The cutoff 
value with highest accuracy (93.9%) was 1.49 x 10-
TABLE 2. Calculation of diagnostic performance of conventional T2W MRI and 
combined set of conventional T2W MRI in addition to DWI for the diagnosis of 
complete rectal cancer response to neoadjuvant therapy
T2W 95% CI T2W + DWI 95% CI
Sensitivity% 86.9 (0.65–0.96) 96.1 (0.78–0.99)
Specificity% 50 (0.20–0.79) 71.4 (0.30–0.94)
PPV% 80 (0.58–0.92) 92.6 (0.74–0.98)
NPV% 62.5 (0.25–0.89) 83.3 (0.36–0.99)
Accuracy% 75.7 (0.57–0.88) 81.8 (0.63–0.92)
95% CI = 95% confidence interval; DWI = diffusion-weighted imaging; T2W = T2-weighted; NPV = 
negative predictive value; PPV = positive predictive value 
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A B
3 mm2/s, with a sensitivity of 100% (95% CI: 0.83 
to 1.00) and specificity of 71.4% (95% CI: 0.30 to 
0.94) (Figure 3A). All patients with residual tumor 
in the surgical specimen were allocated below this 
threshold. 
A histogram was created to estimate the post-
CRT ADC values distribution in a following 
Gaussian distribution population. Its coefficient of 
variation (which is the ratio of the standard devia-
tion to the mean) was 10% and 16% respectively, 
for non-pCR and pCR groups, both values be-
ing considered sufficient for high forecastability. 
Figure 3B depicts the normal distribution based on 
the sample size of this study. 
Discussion 
The growing interest in using DW-MRI through 
its ADC to study tumor behavior is a reality. This 
method is sensitive to the motion of water mol-
ecules, which vary in function in cell membranes 
and intracellular elements, providing potential 
access to the cellular architecture on a millimetric 
scale. Promising results have been described for 
breast cancer, liver metastasis, sarcoma and brain 
tumor.13-17
The demand for an image that allows a reliable 
interpretation of tumor aggressiveness and the 
need for a safety reevaluation of the response to 
neoadjuvant CRT in rectal cancer have stimulated 
research.1-10,18-23 DW-MRI has advantages, such as 
the absence of the use of exogenous contrast and ir-
radiation, it does not induce pain or cause discom-
fort in the patient, besides the fact that DW-MRI 
can be obtained relatively quickly if incorporated 
into routine standard MRI.24,25
This study explored quantitative aspects of the 
ADC in patients with rectal cancer who received 
CRT and it is in line with the growing use of po-
tentially powerful imaging biomarker. This kind 
of radiological approach may allow a better under-
standing of the biological tumors cells behavior, 
and enable a more personalized management, in 
an era focused at less extensive surgeries.24
A B C
FIGURE 2. Correlation between ADC values and final T staging. (A) The pre-CRT ADC values were similar in the different groups (blue bars, (p > 0.05), 
although post-CRT ADC values differed in each group (green bars, p < 0.01); statistical significance (*). (B) Post-CRT ADC values with a moderate 
negative correlation and slope different from zero degrees (Spearman’s Rho = -0.54; 95% confidence interval -0.75 to -0.24). (C) Box plot analysis 
between post-CRT ADC values and final T staging. The pCR ADC-median value (1.53 x 10-3 mm2/s) is far away from the lower and upper boundaries of 
the non-pCR box (p < 0.01).
FIGURE 3. Receiver operating characteristic (ROC) curve and histogram in patients 
with rectal carcinoma with a normal distribution. (A) The optimal post-CRT ADC 
cutoff value 1.49x10-3 mm2/s (area under the curve = 0.95). (B) Histogram. The mean 
post-CRT ADC values of patients with pCR was 1.53 (± 1.96 x0.15x10-3 mm2/s) and of 
patients with non-pCR 1.16 (± 1.96x0.19x10-3 mm2/s); the area in gray highlights the 
possible overlap in these values.
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However, many challenges still exist for wide-
spread implementation of DW-MRI to reevaluate 
rectal cancer after CRT. Koh et al.1, Lambregts et 
al.2, and Engin et al.3 warned that because the meas-
urements and analyzes of this radiological method 
are not yet standardized, the validation and repro-
duction of several studies is difficult due to the 
lack of a uniform methodology among them, thus 
quality assurance is placed at risk. This plurality of 
results was the target of a recent systematic review 
in which we observed a wide range of conflicting 
results.4
In the present study, we first retrospectively 
evaluated the use of conventional MRI alone and 
in addition to DWI in patients undergoing neoad-
juvant CRT and subsequently performed surgery 
for rectal adenocarcinoma. We observed that add-
ing DWI can improve the diagnostic performance 
of conventional MRI, increasing its sensitivity, posi-
tive and negative predictive value, specificity and 
accuracy. Foti et al.31 recently published and de-
scribed the same positive impact of using DWI se-
quences in conventional MRI reading for radiologi-
cal re-assessment of rectal cancer response to CRT.
Other important focus of this study was to eval-
uate the diagnostic performance of ADC values 
pre- and post- neoadjuvant CRT to assess the re-
sponse to treatment, through the correlation with 
histopathological parameters.
No difference was found in the distribution of 
pre-CRT ADC values between pCR and non-pCR 
groups. The possible use of pre-CRT ADC value to 
predict tumor response to CRT was first published 
by Andrzej Dzik-Jurasz et al.28 However, this corre-
lation is controversial, and it was not reproduced 
later, in 6 of 9 published papers, compiled in a re-
cent systematic review.4 Our results also suggest 
lack of differences for pre-CRT ADC to predict the 
final response to therapy. These findings are in 
line with those of Engin et al.3, Kim et al.5, Curvo-
Semedo et al.6, as recently published by Blazic et al.29
Moreover, the analysis of post-CRT ADC values 
was significantly different between patients with 
pCR and those in which the tumor was identified 
in the specimen. The ypT0 group was statistically 
different from the other patients, corroborating the 
findings of Song et al.7 Sun et al.8 proposed that this 
ADC increase reflects the local necrosis and sensi-
tivity of tumors to treatment and is greater in pa-
tients with ypT0 staging, which was also observed 
in this study.
The importance of post-CRT ADC values was 
evident by the increase in the specificity of MRI in 
addition to DWI in 28.6% of scans, increasing from 
71.4% to 100%, considering the cutoff value of 1.32 
x 10-3 mm2/s. Thus, all ypT0 patients were above 
this threshold. This fact has already been described 
by other authors.3,5,9 The maximum sensitivity and 
diagnostic performance of post-CRT ADC values 
was achieved with the cutoff of ADC 1.49 x 10-3 
mm2/s, below which all subjects who had viable tu-
mor in the surgical specimen were allocated. Other 
cutoff values available in the literature ranged from 
1.04 to 1.41 x 10-3 mm2/s.4
The histogram obtained in this study character-
ized this previous phenomenon and allowed an 
inference from the behavior of the curves of post-
CRT ADC values in a population with normal dis-
tribution. Based on the sample in this study, 95% of 
patients with non-pCR had post-CRT ADC values 
between 0.77 and 1.54 x 10-3 mm2/s.
This study has some limitations. First, this was 
a single center, retrospective study that had an 
overall small population without a validation set, 
which may lead inevitable bias. Second, the ADC 
values were obtained in a single slice ROI contain-
ing the whole visible tumor area, which may not 
be fully representative of the overall profile of the 
tumor. Variations in ROI size and positioning can 
effect tumor ADC measurements. However in re-
cent previous studies single slice ROI and whole-
tumor volume methods had comparable diagnos-
tic performance levels with similar AUCs. In this 
context, single slice ROI can be used as a less time 
consuming alternative and relatively efficient ap-
proach for clinical practice, in the assessment of 
tumor response to CRT.29,30 Third, the presence 
of small amount of mucin in specimen, as tumor 
regresses, may have changed the post-CRT ADC 
value, as already observed by others authors.10,26-27 
Fourth, because of the retrospective nature of this 
study, all patients had already been operated on 
when we analyzed the MRIs, thus it was not possi-
ble to perform the dissection and histopathological 
evaluation of each of the suspicious lymph nodes.
Conclusions
This study provides quantitative aspects of the use 
of DW-MRI through the pre- and post-CRT ADC 
values. Our data support the fact that post-CRT 
ADC values increased the overall diagnostic per-
formance of MRI in addition to DWI. In the future, 
larger studies may separate these populations with 
greater precision, revealing and making clear the 
area of interception between the pCR and non-pCR 
groups.
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